- The folks at AbbVie are studying the effects of Veliparib; Carboplatin; Paclitaxel; Doxorubicin; Cyclophosphamide on Triple Negative Breast Cancer in females ages 18 years and older. This clinical trial is slated to start January 2014 and is expected to end circa June 2016.847-938-5570 Brian Oliver, BS
|Recruiting||Brian Oliver, BSfirstname.lastname@example.org||847-938-5570|
This study is officially titled, "A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC)."
|Recruiting||Site Reference ID/Investigator# 116815|
Lafayette, Indiana, 47905
United States - map
For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.